REFERRED TO HEALTH
Email me when A 8576 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track A 8576. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
The bill adds a new section to New York’s public health law that treats settlement agreements between brand‑name drug owners and generic or biosimilar makers as unlawful when the generic company receives a benefit and agrees to stop developing or selling its product. It aims to stop deals that keep lower‑cost drugs off the market, while allowing limited settlements that only grant early marketing rights or modest litigation‑cost reimbursements. The purpose is to keep affordable medicines available to New Yorkers.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about A 8576
3 free questions a day, no accountHistory
- REFERRED TO HEALTH
- REFERRED TO HEALTH
Sponsors
- Anna Kelles · sponsor
- Albert A. Stirpe
- Amanda Septimo
- Amy Paulin
- Andrew Hevesi
- Angelo Santabarbara
- Chantel Jackson
- Charles Lavine
- Chris Burdick
- Dana Levenberg
- Deborah Glick
- Donna Lupardo
- Doug Smith
- Harvey Epstein
- Jeffrey Dinowitz
- Jessica Gonzalez-Rojas
- Jo Anne Simon
- Jonathan Rivera
- Judy Griffin
- Karines Reyes
- Linda Rosenthal
- Maritza Davila
- Phara Souffrant Forrest
- Phil Steck
- Rodneyse Bichotte Hermelyn
And 2 more cosponsors.
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when A 8576 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track A 8576 freeOr ask your AI assistant about A 8576 directly:
Add to Claude, ChatGPT or Cursor